- Home
- NRG vs ONC Comparison
NRG vs ONC Comparison
Compare NRG & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRG | ONC |
|---|---|---|
| Founded | 1989 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9B | 34.8B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | NRG | ONC |
|---|---|---|
| Price | $149.21 | $347.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | $188.86 | ★ $369.50 |
| AVG Volume (30 Days) | ★ 1.9M | 323.3K |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | ★ 62.56 | N/A |
| EPS | ★ 6.78 | 0.58 |
| Revenue | ★ $29,779,000,000.00 | $4,972,687,000.00 |
| Revenue This Year | $6.86 | $895.40 |
| Revenue Next Year | $15.77 | $22.04 |
| P/E Ratio | ★ $21.98 | $571.21 |
| Revenue Growth | 5.91 | ★ 50.43 |
| 52 Week Low | $79.57 | $174.74 |
| 52 Week High | $180.54 | $385.22 |
Technical Indicators
Market Signals| Indicator | NRG | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 40.57 | 63.03 |
| Support Level | $146.00 | $317.97 |
| Resistance Level | $151.79 | $335.32 |
| Average True Range (ATR) | 4.96 | 8.52 |
| MACD | -1.03 | 4.36 |
| Stochastic Oscillator | 26.28 | 96.63 |
Price Performance
Historical ComparisonAbout NRG NRG Energy Inc.
NRG Energy is one of the largest retail energy providers in the US, with 6 million customers. Vivint Smart Home, which NRG acquired in 2023, has 2 million home-services customers. NRG also is one of the largest US independent power producers, with 13 gigawatts of coal, gas, and oil power generation capacity primarily in Texas. The LS Power asset acquisition adds 13 GW of gas-fired power plants mostly in the Eastern US. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.